{"id":"ruboxistaurin","rwe":[],"tags":[{"label":"ruboxistaurin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Protein kinase C theta type","category":"target"},{"label":"PRKCQ","category":"gene"},{"label":"PRKCD","category":"gene"},{"label":"PRKCB","category":"gene"},{"label":"Active","category":"status"},{"label":"Enzyme Inhibitors","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["ruboxistaurin mesilate monohydrate","ruboxistaurin mesilate","ruboxistaurin mesylate","ruboxistaurin"],"offLabel":[],"synonyms":["ruboxistaurin mesilate monohydrate","ruboxistaurin mesilate","ruboxistaurin mesylate","ruboxistaurin"],"timeline":[],"aiSummary":"RUBOXISTAURIN is a small molecule drug that targets Protein Kinase C theta type. It is classified as a ruboxistaurin, but its commercial status and approved indications are unknown. The mechanism of action involves inhibiting Protein Kinase C theta type, which plays a role in inflammation and fibrosis. As a result, RUBOXISTAURIN may be used to treat conditions associated with these processes. However, its development and approval status are unclear.","approvals":[],"ecosystem":[],"mechanism":{"target":"Citron Rho-interacting kinase, Homeodomain-interacting protein kinase 1, Homeodomain-interacting protein kinase 3","targets":[{"gene":"PRKCQ","source":"DrugCentral","target":"Protein kinase C theta type","protein":"Protein kinase C theta type"},{"gene":"PRKCD","source":"DrugCentral","target":"Protein kinase C delta type","protein":"Protein kinase C delta type"},{"gene":"PRKCB","source":"DrugCentral","target":"Protein kinase C beta type","protein":"Protein kinase C beta type"},{"gene":"PRKCE","source":"DrugCentral","target":"Protein kinase C epsilon type","protein":"Protein kinase C epsilon type"},{"gene":"PIM3","source":"DrugCentral","target":"Serine/threonine-protein kinase pim-3","protein":"Serine/threonine-protein kinase pim-3"},{"gene":"MAP3K19","source":"DrugCentral","target":"Mitogen-activated protein kinase kinase kinase 19","protein":"Mitogen-activated protein kinase kinase kinase 19"},{"gene":"PIM1","source":"DrugCentral","target":"Serine/threonine-protein kinase pim-1","protein":"Serine/threonine-protein kinase pim-1"},{"gene":"HIPK3","source":"DrugCentral","target":"Homeodomain-interacting protein kinase 3","protein":"Homeodomain-interacting protein kinase 3"},{"gene":"MAPK15","source":"DrugCentral","target":"Mitogen-activated protein kinase 15","protein":"Mitogen-activated protein kinase 15"},{"gene":"TAOK3","source":"DrugCentral","target":"Serine/threonine-protein kinase TAO3","protein":"Serine/threonine-protein kinase TAO3"}],"modality":"Small Molecule","drugClass":"ruboxistaurin","explanation":"Think of Protein Kinase C theta type like a messenger that helps cells talk to each other. When this messenger gets out of control, it can lead to inflammation and scarring. RUBOXISTAURIN acts like a brake, slowing down this messenger to prevent excessive inflammation and fibrosis.","oneSentence":"RUBOXISTAURIN works by blocking a specific enzyme called Protein Kinase C theta type, which is involved in inflammation and fibrosis.","technicalDetail":"RUBOXISTAURIN selectively inhibits Protein Kinase C theta (PKCθ), a member of the novel protein kinase C family, which plays a critical role in T-cell activation and cytokine production."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3533","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=RUBOXISTAURIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RUBOXISTAURIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:34:28.164085","biosimilars":[],"competitors":[{"drugName":"abrocitinib","drugSlug":"abrocitinib","fdaApproval":"2022-01-14","patentExpiry":"Jan 14, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"acalabrutinib","drugSlug":"acalabrutinib","fdaApproval":"2017-10-31","patentExpiry":"Nov 24, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"axitinib","drugSlug":"axitinib","fdaApproval":"2012-01-27","patentExpiry":"Jun 14, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"baricitinib","drugSlug":"baricitinib","fdaApproval":"2018-05-31","patentExpiry":"Nov 30, 2032","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bosutinib","drugSlug":"bosutinib","fdaApproval":"2012-09-04","patentExpiry":"Nov 23, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"ceritinib","drugSlug":"ceritinib","fdaApproval":"2014-04-29","patentExpiry":"Nov 20, 2027","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"crizotinib","drugSlug":"crizotinib","fdaApproval":"2011-08-26","patentExpiry":"Oct 8, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dacomitinib","drugSlug":"dacomitinib","fdaApproval":"2018-09-27","patentExpiry":"Sep 27, 2032","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dasatinib","drugSlug":"dasatinib","fdaApproval":"2006-06-28","patentExpiry":"Sep 28, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"entrectinib","drugSlug":"entrectinib","fdaApproval":"2019-08-15","patentExpiry":"May 22, 2033","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"ruboxistaurin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"abrocitinib","brandName":"abrocitinib","genericName":"abrocitinib","approvalYear":"2022","relationship":"same-target"},{"drugId":"acalabrutinib","brandName":"acalabrutinib","genericName":"acalabrutinib","approvalYear":"2017","relationship":"same-target"},{"drugId":"axitinib","brandName":"axitinib","genericName":"axitinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"baricitinib","brandName":"baricitinib","genericName":"baricitinib","approvalYear":"2018","relationship":"same-target"},{"drugId":"bosutinib","brandName":"bosutinib","genericName":"bosutinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"ceritinib","brandName":"ceritinib","genericName":"ceritinib","approvalYear":"2014","relationship":"same-target"},{"drugId":"crizotinib","brandName":"crizotinib","genericName":"crizotinib","approvalYear":"2011","relationship":"same-target"},{"drugId":"dacomitinib","brandName":"dacomitinib","genericName":"dacomitinib","approvalYear":"2018","relationship":"same-target"},{"drugId":"dasatinib","brandName":"dasatinib","genericName":"dasatinib","approvalYear":"2006","relationship":"same-target"},{"drugId":"entrectinib","brandName":"entrectinib","genericName":"entrectinib","approvalYear":"2019","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05511948","phase":"PHASE2","title":"Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos","status":"COMPLETED","sponsor":"DermBiont, Inc.","startDate":"2022-08-18","conditions":["Hyperpigmentation"],"enrollment":75,"completionDate":"2023-03-07"},{"nctId":"NCT02769611","phase":"PHASE1,PHASE2","title":"Ruboxistaurin in New York Heart Failure Classification III-IV Patients","status":"WITHDRAWN","sponsor":"University of Tennessee","startDate":"2017-06-28","conditions":["Heart Failure"],"enrollment":0,"completionDate":"2022-01-01"},{"nctId":"NCT00044148","phase":"PHASE2","title":"The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2002-07-16","conditions":["Diabetic Nephropathy"],"enrollment":0,"completionDate":"2004-04-28"},{"nctId":"NCT00090519","phase":"PHASE3","title":"Reduction in the Occurrence of Center-Involved Diabetic Macular Edema","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2004-02","conditions":["Diabetic Retinopathy"],"enrollment":731,"completionDate":"2010-04"},{"nctId":"NCT00133952","phase":"PHASE3","title":"Effect of Ruboxistaurin on Clinically Significant Macular Edema","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2005-08","conditions":["Diabetic Macular Edema"],"enrollment":309,"completionDate":"2011-07"},{"nctId":"NCT00266695","phase":"PHASE3","title":"Treatment for Completers of the Study B7A-MC-MBCM","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2006-01","conditions":["Diabetic Retinopathy"],"enrollment":203,"completionDate":"2008-08"},{"nctId":"NCT00604383","phase":"PHASE3","title":"Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2001-03","conditions":["Diabetic Retinopathy"],"enrollment":685,"completionDate":"2005-06"},{"nctId":"NCT00297401","phase":"PHASE3","title":"Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2006-03","conditions":["Diabetes Mellitus, Type 1"],"enrollment":20,"completionDate":"2007-11"},{"nctId":"NCT00044408","phase":"PHASE3","title":"Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2002-07","conditions":["Diabetic Neuropathies","Diabetes Mellitus, Insulin-Dependent","Diabetes Mellitus, Non-Insulin-Dependent"],"enrollment":200,"completionDate":"2005-10"},{"nctId":"NCT00190970","phase":"PHASE2","title":"The Effect of Ruboxistaurin on Small Fiber Function","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2004-10","conditions":["Diabetic Neuropathy"],"enrollment":52,"completionDate":"2005-11"},{"nctId":"NCT00482976","phase":"PHASE2","title":"Effect of LY333531 on Vascular and Neural Functions","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2003-12","conditions":["Diabetes Mellitus"],"enrollment":30,"completionDate":"2005-03"},{"nctId":"NCT00552227","phase":"PHASE1","title":"Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2002-09","conditions":["Diabetes Mellitus"],"enrollment":48,"completionDate":"2005-07"},{"nctId":"NCT00761852","phase":"PHASE2,PHASE3","title":"Signaling Mechanisms and Vascular Function in Diabetes Mellitus","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"1999-05","conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"],"enrollment":30,"completionDate":"2007-10"},{"nctId":"NCT00044395","phase":"PHASE3","title":"Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-07","conditions":["Diabetic Neuropathies","Diabetes Mellitus, Insulin-Dependent","Diabetes Mellitus, Non-Insulin-Dependent"],"enrollment":200,"completionDate":"2005-10"},{"nctId":"NCT00044421","phase":"PHASE3","title":"Treatment of Peripheral Neuropathy in Patients With Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-07","conditions":["Diabetic Neuropathies","Diabetes Mellitus"],"enrollment":400,"completionDate":"2006-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"721809WQCP","VANDF":"4025269","INN_ID":"8108","UMLSCUI":"C1307704","ChEMBL_ID":"CHEMBL91829","DRUGBANK_ID":"DB11829","PDB_CHEM_ID":"LY4","PUBCHEM_CID":"153999","IUPHAR_LIGAND_ID":"5263","SECONDARY_CAS_RN":"192050-59-2","MESH_SUPPLEMENTAL_RECORD_UI":"C099154"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":175,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","brandName":"RUBOXISTAURIN","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"application withdrawn","approval_date":null,"mah":null,"brand_name_local":"Arxxant","application_number":"EMEA/H/C/000753"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Arxxant","application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}